Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793099 | 0.85 | LMNA (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6798581 | 0.84 | OPRM1 (0.33) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6793129 | 0.83 | MEN1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6791586 | 0.81 | MEN1 (0.36) | MEN1KMT2AADORA3TGFBR1TGFBR2 | |
| SCHEMBL6798834 | 0.80 | DRD2 (0.36) | ADORA3 | |
| SCHEMBL6794835 | 0.80 | OPRD1 (0.35) | ALDH1A1 | |
| SCHEMBL6792068 | 0.80 | MEN1 (0.36) | MEN1KMT2AADORA3TGFBR1TGFBR2 | |
| SCHEMBL6790712 | 0.79 | P2RY12 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6792555 | 0.73 | AURKA (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6793946 | 0.72 | CCNA2 (0.37) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MEN1 1382/4885KMT2A 1257/4885ADORA3 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.